1. all adult lung transplant recipients (age ≥ 18 at the time of consent) who received all of their covid-19 vaccines after lung transplantation. 2. received three or four doses of either the moderna mrna-1273 or pfizer bnt162b2 vaccine with the last dose received at least 4 months prior to study enrollment. 3. currently receiving standard regimen of three drug immunosuppression with prednisone, tacrolimus and mycophenolate mofetil (cellcept, minimum 250 mg bid) or mycophenolate sodium (myfortic, minimum 180 mg bid). 4. agrees not to receive other investigational agents for prophylaxis against covid-19 including evusheld monoclonal antibodies for at least 30 days after the study vaccine. 5. understands and agrees to comply with the study procedures and provides written informed consent. 6. is in stable health without any new or worsening medical conditions in the opinion of the investigator. 7. female participants of childbearing potential (\<1 year since start of menopause) may be enrolled in the study if the participant fulfills all the following criteria: 1. has a negative pregnancy test at visit 1 day 1. 2. has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection (day 1). 3. has agreed to continue adequate contraception or practice abstinence through 3 months following the booster injection (day 90). 4. is not currently breastfeeding. 5. adequate female contraception is defined as consistent and correct use of a food and drug administration (fda) approved contraceptive method in accordance with the product label. for example: i. barrier method (such as condoms, diaphragm, or cervical cap) used in conjunction with spermicide ii. intrauterine device iii. prescription hormonal contraceptive taken or administered via oral (pill), transdermal (patch), subdermal, or im route iv. sterilization of a female participant's monogamous male partner prior to entry into the study v. note: periodic abstinence (e.g., calendar, ovulation methods) and withdrawal are not acceptable methods of contraception.

1. all adult lung transplant recipients (age ≥ 18 at the time of consent) who received all of their covid-19 vaccines after lung transplantation. 2. received three or four doses of either the moderna mrna-1273 or pfizer bnt162b2 vaccine with the last dose received at least 4 months prior to study enrollment. 3. currently receiving standard regimen of three drug immunosuppression with prednisone, tacrolimus and mycophenolate mofetil (cellcept, minimum 250 mg bid) or mycophenolate sodium (myfortic, minimum 180 mg bid). 4. agrees not to receive other investigational agents for prophylaxis against covid-19 including evusheld monoclonal antibodies for at least 30 days after the study vaccine. 5. understands and agrees to comply with the study procedures and provides written informed consent. 6. is in stable health without any new or worsening medical conditions in the opinion of the investigator. 7. female participants of childbearing potential (\<1 year since start of menopause) may be enrolled in the study if the participant fulfills all the following criteria: 1. has a negative pregnancy test at visit 1 day 1. 2. has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection (day 1). 3. has agreed to continue adequate contraception or practice abstinence through 3 months following the booster injection (day 90). 4. is not currently breastfeeding. 5. adequate female contraception is defined as consistent and correct use of a food and drug administration (fda) approved contraceptive method in accordance with the product label. for example: i. barrier method (such as condoms, diaphragm, or cervical cap) used in conjunction with spermicide ii. intrauterine device iii. prescription hormonal contraceptive taken or administered via oral (pill), transdermal (patch), subdermal, or im route iv. sterilization of a female participant's monogamous male partner prior to entry into the study v. note: periodic abstinence (e.g., calendar, ovulation methods) and withdrawal are not acceptable methods of contraception.

all adult lung transplant recipients (age ≥ 18 at the time of consent) who received all of their covid-19 vaccines after lung transplantation. received three or four doses of either the moderna mrna-1273 or pfizer bnt162b2 vaccine with the last dose received at least 4 months prior to study enrollment. currently receiving standard regimen of three drug immunosuppression with prednisone, tacrolimus and mycophenolate mofetil (cellcept, minimum 250 mg bid) or mycophenolate sodium (myfortic, minimum 180 mg bid). agrees not to receive other investigational agents for prophylaxis against covid-19 including evusheld monoclonal antibodies for at least 30 days after the study vaccine. understands and agrees to comply with the study procedures and provides written informed consent. is in stable health without any new or worsening medical conditions in the opinion of the investigator. female participants of childbearing potential (<1 year since start of menopause) may be enrolled in the study if the participant fulfills all the following criteria: has a negative pregnancy test at visit 1 day 1. has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection (day 1). has agreed to continue adequate contraception or practice abstinence through 3 months following the booster injection (day 90). is not currently breastfeeding. adequate female contraception is defined as consistent and correct use of a food and drug administration (fda) approved contraceptive method in accordance with the product label. for example: i. barrier method (such as condoms, diaphragm, or cervical cap) used in conjunction with spermicide ii. intrauterine device iii. prescription hormonal contraceptive taken or administered via oral (pill), transdermal (patch), subdermal, or im route iv. sterilization of a female participant's monogamous male partner prior to entry into the study v. note: periodic abstinence (e.g., calendar, ovulation methods) and withdrawal are not acceptable methods of contraception.

all adult lung transplant recipients (age ≥ 18 at the time of consent) who received all of their covid-19 vaccines after lung transplantation. received three or four doses of either the moderna mrna-1273 or pfizer bnt162b2 vaccine with the last dose received at least 4 months prior to study enrollment. currently receiving standard regimen of three drug immunosuppression with prednisone, tacrolimus and mycophenolate mofetil (cellcept, minimum 250 mg bid) or mycophenolate sodium (myfortic, minimum 180 mg bid). agrees not to receive other investigational agents for prophylaxis against covid-19 including evusheld monoclonal antibodies for at least 30 days after the study vaccine. understands and agrees to comply with the study procedures and provides written informed consent. is in stable health without any new or worsening medical conditions in the opinion of the investigator. female participants of childbearing potential (<1 year since start of menopause) may be enrolled in the study if the participant fulfills all the following criteria: has a negative pregnancy test at visit 1 day 1. has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection (day 1). has agreed to continue adequate contraception or practice abstinence through 3 months following the booster injection (day 90). is not currently breastfeeding. adequate female contraception is defined as consistent and correct use of a food and drug administration (fda) approved contraceptive method in accordance with the product label. for example: i. barrier method (such as condoms, diaphragm, or cervical cap) used in conjunction with spermicide ii. intrauterine device iii. prescription hormonal contraceptive taken or administered via oral (pill), transdermal (patch), subdermal, or im route iv. sterilization of a female participant's monogamous male partner prior to entry into the study v. note: periodic abstinence (e.g., calendar, ovulation methods) and withdrawal are not acceptable methods of contraception.

inclusion criteria: all adult lung transplant recipients (age≥18) who received all of their covid-19 vaccines after lung transplantation.. received three doses of the moderna mrna-1273 vaccine at least 3 months prior to study enrollment. currently receiving standard regimen of three drug immunosuppression with prednisone, tacrolimus and mycophenolate (minimum 500 mg bid) or myfortic (minimum 360 mg bid). agrees not to receive other investigational agents for prophylaxis against covid-19 including evusheld monoclonal antibodies for at least 30 days after the study vaccine. understands and agrees to comply with the study procedures and provides written informed consent. is in stable health without any new or worsening medical conditions in the opinion of the investigator. body mass index (bmi) of 16 kg/m2 to 36 kg/m2 (inclusive) at the visit1 day 1 (booster day). female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria: has a negative pregnancy test at visit 1 day 1. has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection (day 1). has agreed to continue adequate contraception or practice abstinence through 3 months following the booster injection (day 90). is not currently breastfeeding. adequate female contraception is defined as consistent and correct use of a food and drug administration (fda) approved contraceptive method in accordance with the product label. for example: i. barrier method (such as condoms, diaphragm, or cervical cap) used in conjunction with spermicide ii. intrauterine device iii. prescription hormonal contraceptive taken or administered via oral (pill), transdermal (patch), subdermal, or im route iv. sterilization of a female participant's monogamous male partner prior to entry into the study v. note: periodic abstinence (e.g., calendar, ovulation methods) and withdrawal are not acceptable methods of contraception.

inclusion criteria: all adult lung transplant recipients (age≥18) who received all of their covid-19 vaccines after lung transplantation.. received three doses of the moderna mrna-1273 vaccine at least 3 months prior to study enrollment. currently receiving standard regimen of three drug immunosuppression with prednisone, tacrolimus and mycophenolate (minimum 500 mg bid) or myfortic (minimum 360 mg bid). agrees not to receive other investigational agents for prophylaxis against covid-19 including evusheld monoclonal antibodies for at least 30 days after the study vaccine. understands and agrees to comply with the study procedures and provides written informed consent. is in stable health without any new or worsening medical conditions in the opinion of the investigator. body mass index (bmi) of 16 kg/m2 to 36 kg/m2 (inclusive) at the visit1 day 1 (booster day). female participants of childbearing potential may be enrolled in the study if the participant fulfills all the following criteria: has a negative pregnancy test at visit 1 day 1. has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection (day 1). has agreed to continue adequate contraception or practice abstinence through 3 months following the booster injection (day 90). is not currently breastfeeding. adequate female contraception is defined as consistent and correct use of a food and drug administration (fda) approved contraceptive method in accordance with the product label. for example: i. barrier method (such as condoms, diaphragm, or cervical cap) used in conjunction with spermicide ii. intrauterine device iii. prescription hormonal contraceptive taken or administered via oral (pill), transdermal (patch), subdermal, or im route iv. sterilization of a female participant's monogamous male partner prior to entry into the study v. note: periodic abstinence (e.g., calendar, ovulation methods) and withdrawal are not acceptable methods of contraception.